Details of the Drug

General Information of Drug (ID: DM4LT8A)

Drug Name
Dapsone
Synonyms
Aczone; Atrisone; Avlosulfon; Avlosulfone; Avlosulphone; Avsulfor; Croysulfone; Croysulphone; DADPS; DDS; Dapson; Dapsona; Dapsonum; Diaminodifenilsulfona; Diaminodiphenylsulfone; Diaphenylsulfon; Diaphenylsulfone; Diaphenylsulphon; Diaphenylsulphone; Diphenasone; Diphone; Disulone; Dubronax; Dubronaz; Dumitone; Eporal; Novophone; Protogen; Sulfadione; Sulfona; Sulfonyldianiline; Sulphadione; Sulphonyldianiline; Tarimyl; Udolac; Araldite HT; D SS; Diaminodifenilsulfona [Spanish]; Diaminodiphenyl sulfone;Fatol Brand of Dapsone; Metabolite C; Orsade Brand of Dapsone; Sulfone ucb; Sumicure S; Araldite HT 976; F 1358; HT 976; HY 976; Hardener HT 976; W R 448; WR 448; ALBB-005917; AZT + Dapsone cominbation; Aczone (TN); DDS (pharmaceutical); DDS, diaphenylsulfone; DDS, pharmaceutical; DSS (VAN); Dapsoderm-X; Dapson-Fatol; Dapsona [INN-Spanish]; Dapsone (USP); Dapsone [USAN:BAN]; Dapsonum [INN-Latin];Diamino-diphenyl sulphone; Diaphenylsulfone (JAN); IN-201; Mex-America Brand of Dapsone; P-Aminophenyl sulfone; Sulfanona-mae; Sulfon-mere; Sulfona-MAE; Sulphon-mere; Bis(4-aminophenyl) sulfone; Bis(4-aminophenyl)sulfone; Bis(4-aminophenyl)sulphone; Bis(p-aminophenyl) sulfone; Bis(p-aminophenyl)sulphone; Di(4-aminophenyl) sulfone; Di(4-aminophenyl)sulfone; Di(4-aminophenyl)sulphone; Di(p-aminophenyl) sulfone; Di(p-aminophenyl)sulphone; P,p-Diaminodiphenyl sulphone; P,p-Sulfonylbisbenzamine; P,p-Sulfonylbisbenzenamine; P,p-Sulphonylbisbenzamine; P,p-Sulphonylbisbenzenamine; P,p-Sulphonyldianiline; N, N'-Diphenyl sulfondiamide; N,N'-Diphenyl sulfondiamide; P, p'-Sulfonyldianiline; P,p'-Diaminodiphenyl sulfone; P,p'-sulfonyldianiline; Diamino-4,4'-diphenyl sulfone; Diamino-4,4'-diphenyl sulphone; Sulfone, 4,4'-Diaminophenyl; (4-sulfanilylphenyl)amine; 1,1'-Sulfonylbis(4-aminobenzene); 1,1'-Sulfonylbis[4-aminobenzene]; 1,1'-Sulphonylbis(4-aminobenzene); 4,4' Diaminophenyl Sulfone; 4,4'-Dapsone; 4,4'-Diaminodiphenyl sulfone; 4,4'-Diaminodiphenyl suphone; 4,4'-Diaminodiphenylsulfone; 4,4'-Sulfonylbisaniline; 4,4'-Sulfonylbisbenzamine; 4,4'-Sulfonylbisbenzenamine; 4,4'-Sulfonyldianiline;4,4'-Sulfonyldianiline (Dapsone); 4,4'-Sulphonylbisbenzamine; 4,4'-Sulphonylbisbenzenamine; 4,4'-Sulphonyldianiline; 4,4'-diaminophenyl sulfone; 4,4-Diaminodifenylsulfon; 4,4-Diaminodifenylsulfon [Czech]; 4,4-Sulfonyldianiline; 4-(4-aminophenyl)sulfonylaniline; 4-Aminop henyl sulfone; 4-Aminophenyl sulfone; 4-Aminophenylsulfone; 4-[(4-aminobenzene)sulfonyl]aniline; 4-[(4-aminophenyl)sulfonyl]aniline
Indication
Disease Entry ICD 11 Status REF
Pneumocystis pneumonia CA40.20 Approved [1]
Therapeutic Class
Antiinflammatory Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 248.3
Topological Polar Surface Area (xlogp) 1
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 4
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [2]
Bioavailability
The bioavailability of drug is 70-80% [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 0.48 mL/min/kg [4]
Elimination
The drug is excreted via renal [5]
Half-life
The concentration or amount of drug in body reduced by one-half in 28 (range 10 - 50) hours [4]
Metabolism
The drug is metabolized via the hepatic [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 20.13647 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.25% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.83 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.2 mg/mL [2]
Chemical Identifiers
Formula
C12H12N2O2S
IUPAC Name
4-(4-aminophenyl)sulfonylaniline
Canonical SMILES
C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N
InChI
InChI=1S/C12H12N2O2S/c13-9-1-5-11(6-2-9)17(15,16)12-7-3-10(14)4-8-12/h1-8H,13-14H2
InChIKey
MQJKPEGWNLWLTK-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2955
ChEBI ID
CHEBI:4325
CAS Number
80-08-0
DrugBank ID
DB00250
TTD ID
D0MA9N
INTEDE ID
DR0415
ACDINA ID
D00168

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Pneumocystis carinii Dihydropteroate synthase (PC DHPS) TT6NHYC FOL1_PNECA Modulator [7]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [8]
Cytochrome P450 2E1 (CYP2E1)
Main DME 		DEVDYN7 CP2E1_HUMAN Substrate [9]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [10]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [9]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [11]
Prostaglandin G/H synthase 2 (COX-2) DE492CE PGH2_HUMAN Substrate [12]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Substrate [9]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [11]
Prostaglandin G/H synthase 1 (COX-1) DE073H6 PGH1_HUMAN Substrate [12]
Cytochrome P450 2C18 (CYP2C18) DEZMWRE CP2CI_HUMAN Substrate [9]
Myeloperoxidase (MPO) DEA3U9Y PERM_HUMAN Substrate [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Dapsone
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Lefamulin DME6G97 Moderate Decreased metabolism of Dapsone caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [77]
Coadministration of a Drug Treating the Disease Different from Dapsone (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Nateglinide DMLK2QH Moderate Decreased metabolism of Dapsone caused by Nateglinide mediated inhibition of CYP450 enzyme. Acute diabete complication [5A2Y] [78]
Ivosidenib DM8S6T7 Minor Increased metabolism of Dapsone caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [79]
Arn-509 DMT81LZ Moderate Increased metabolism of Dapsone caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [80]
Mitotane DMU1GX0 Minor Increased metabolism of Dapsone caused by Mitotane mediated induction of CYP450 enzyme. Adrenal cancer [2D11] [79]
Methylphenobarbital DMDSWAG Minor Increased metabolism of Dapsone caused by Methylphenobarbital mediated induction of CYP450 enzyme. Anxiety disorder [6B00-6B0Z] [79]
Voriconazole DMAOL2S Moderate Decreased metabolism of Dapsone caused by Voriconazole mediated inhibition of CYP450 enzyme. Aspergillosis [1F20] [81]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Dapsone caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [82]
Pexidartinib DMS2J0Z Minor Increased metabolism of Dapsone caused by Pexidartinib mediated induction of CYP450 enzyme. Bone/articular cartilage neoplasm [2F7B] [79]
Lapatinib DM3BH1Y Moderate Decreased metabolism of Dapsone caused by Lapatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [83]
Alpelisib DMEXMYK Moderate Increased metabolism of Dapsone caused by Alpelisib mediated induction of CYP450 enzyme. Breast cancer [2C60-2C6Y] [84]
Grepafloxacin DMGLX0T Moderate Decreased metabolism of Dapsone caused by Grepafloxacin mediated inhibition of CYP450 enzyme. Bronchitis [CA20] [85]
Secobarbital DM14RF5 Minor Increased metabolism of Dapsone caused by Secobarbital mediated induction of CYP450 enzyme. Chronic insomnia [7A00] [79]
Phenylbutazone DMAYL0T Minor Increased metabolism of Dapsone caused by Phenylbutazone mediated induction of CYP450 enzyme. Chronic pain [MG30] [79]
Mifepristone DMGZQEF Moderate Decreased metabolism of Dapsone caused by Mifepristone mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [86]
Aminoglutethimide DMWFHMZ Minor Increased metabolism of Dapsone caused by Aminoglutethimide mediated induction of CYP450 enzyme. Cushing syndrome [5A70] [79]
Lumacaftor DMCLWDJ Minor Increased metabolism of Dapsone caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [79]
Ivacaftor DMZC1HS Moderate Decreased metabolism of Dapsone caused by Ivacaftor mediated inhibition of CYP450 enzyme. Cystic fibrosis [CA25] [87]
MK-8228 DMOB58Q Moderate Increased metabolism of Dapsone caused by MK-8228 mediated induction of CYP450 enzyme. Cytomegaloviral disease [1D82] [88]
Aprepitant DM053KT Moderate Decreased metabolism of Dapsone caused by Aprepitant mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [89]
Nefazodone DM4ZS8M Moderate Decreased metabolism of Dapsone caused by Nefazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [90]
Griseofulvin DMK54YG Minor Increased metabolism of Dapsone caused by Griseofulvin mediated induction of CYP450 enzyme. Dermatophytosis [1F28] [79]
Primidone DM0WX6I Minor Increased metabolism of Dapsone caused by Primidone mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [79]
Felbamate DM1V5ZS Minor Increased metabolism of Dapsone caused by Felbamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [79]
Oxcarbazepine DM5PU6O Minor Increased metabolism of Dapsone caused by Oxcarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [79]
Cenobamate DMGOVHA Minor Increased metabolism of Dapsone caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [79]
Phenytoin DMNOKBV Minor Increased metabolism of Dapsone caused by Phenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [79]
Fosphenytoin DMOX3LB Minor Increased metabolism of Dapsone caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [79]
Rufinamide DMWE60C Moderate Increased metabolism of Dapsone caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [80]
Phenobarbital DMXZOCG Minor Increased metabolism of Dapsone caused by Phenobarbital mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [79]
Carbamazepine DMZOLBI Minor Increased metabolism of Dapsone caused by Carbamazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [79]
Eslicarbazepine DMZREFQ Minor Increased metabolism of Dapsone caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [79]
Tazemetostat DMWP1BH Minor Increased metabolism of Dapsone caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [79]
Itraconazole DMCR1MV Moderate Decreased metabolism of Dapsone caused by Itraconazole mediated inhibition of CYP450 enzyme. Fungal infection [1F29-1F2F] [91]
Sulfinpyrazone DMEV954 Minor Increased metabolism of Dapsone caused by Sulfinpyrazone mediated induction of CYP450 enzyme. Gout [FA25] [79]
Rifampin DMA8J1G Moderate Increased metabolism of Dapsone caused by Rifampin mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [92]
Rifapentine DMCHV4I Moderate Increased metabolism of Dapsone caused by Rifapentine mediated induction of CYP450 enzyme. HIV-infected patients with tuberculosis [1B10-1B14] [93]
Brentuximab vedotin DMWLC57 Moderate Increased risk of peripheral neuropathy by the combination of Dapsone and Brentuximab vedotin. Hodgkin lymphoma [2B30] [94]
Efavirenz DMC0GSJ Moderate Increased metabolism of Dapsone caused by Efavirenz mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [95]
Saquinavir DMG814N Major Decreased metabolism of Dapsone caused by Saquinavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [81]
Etravirine DMGV8QU Moderate Increased metabolism of Dapsone caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [96]
Zalcitabine DMH7MUV Moderate Increased risk of peripheral neuropathy by the combination of Dapsone and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [97]
Ritonavir DMU764S Moderate Decreased metabolism of Dapsone caused by Ritonavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [98]
Fenofibrate DMFKXDY Moderate Decreased metabolism of Dapsone caused by Fenofibrate mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [81]
Diltiazem DMAI7ZV Moderate Decreased metabolism of Dapsone caused by Diltiazem mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [99]
Probenecid DMMFWOJ Moderate Decreased elimination of Dapsone caused by Probenecid mediated competitive inhibition of renal tubular secretion. Inborn purine/pyrimidine/nucleotide metabolism error [5C55] [100]
Amobarbital DM0GQ8N Minor Increased metabolism of Dapsone caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [79]
Pentobarbital DMFNH7L Minor Increased metabolism of Dapsone caused by Pentobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [79]
Porfimer Sodium DM7ZWNY Moderate Increased risk of photosensitivity reactions by the combination of Dapsone and Porfimer Sodium. Lung cancer [2C25] [101]
Ceritinib DMB920Z Moderate Decreased metabolism of Dapsone caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [81]
PF-06463922 DMKM7EW Moderate Increased metabolism of Dapsone caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [102]
Vemurafenib DM62UG5 Minor Increased metabolism of Dapsone caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [79]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Dapsone caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [80]
Nitisinone DMVS9WQ Moderate Decreased metabolism of Dapsone caused by Nitisinone mediated inhibition of CYP450 enzyme. Metabolism inborn error [5C50] [103]
Thalidomide DM70BU5 Moderate Increased risk of peripheral neuropathy by the combination of Dapsone and Thalidomide. Multiple myeloma [2A83] [97]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Dapsone and Ocrelizumab. Multiple sclerosis [8A40] [104]
Rifabutin DM1YBHK Moderate Increased metabolism of Dapsone caused by Rifabutin mediated induction of CYP450 enzyme. Mycobacterium infection [1B10-1B21] [103]
Methoxsalen DME8FZ9 Moderate Increased risk of photosensitivity reactions by the combination of Dapsone and Methoxsalen. Mycosis fungoides [2B01] [81]
Bexarotene DMOBIKY Minor Increased metabolism of Dapsone caused by Bexarotene mediated induction of CYP450 enzyme. Mycosis fungoides [2B01] [79]
Nilotinib DM7HXWT Moderate Decreased metabolism of Dapsone caused by Nilotinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [105]
Imatinib DM7RJXL Moderate Decreased metabolism of Dapsone caused by Imatinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [106]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Dapsone and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [107]
Modafinil DMYILBE Minor Increased metabolism of Dapsone caused by Modafinil mediated induction of CYP450 enzyme. Narcolepsy [7A20] [108]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Dapsone caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [109]
Prilocaine DMI7DZ2 Major Increased risk of methemoglobinemia by the combination of Dapsone and Prilocaine. Pain [MG30-MG3Z] [110]
Abametapir DM2RX0I Moderate Decreased metabolism of Dapsone caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [111]
Prednisone DM2HG4X Minor Increased metabolism of Dapsone caused by Prednisone mediated induction of CYP450 enzyme. Postoperative inflammation [1A00-CA43] [79]
Enzalutamide DMGL19D Moderate Increased metabolism of Dapsone caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [112]
Verteporfin DMIY6DB Moderate Increased risk of photosensitivity reactions by the combination of Dapsone and Verteporfin. Psoriasis [EA90] [80]
Bosentan DMIOGBU Moderate Increased metabolism of Dapsone caused by Bosentan mediated induction of CYP450 enzyme. Pulmonary hypertension [BB01] [113]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Dapsone and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [114]
Dexamethasone DMMWZET Minor Increased metabolism of Dapsone caused by Dexamethasone mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [79]
Nafcillin DMN9RPO Minor Increased metabolism of Dapsone caused by Nafcillin mediated induction of CYP450 enzyme. Rheumatoid arthritis [FA20] [79]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Dapsone caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [80]
Armodafinil DMGB035 Minor Increased metabolism of Dapsone caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [108]
LEE011 DMMX75K Moderate Decreased metabolism of Dapsone caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [115]
Prednisolone DMQ8FR2 Minor Increased metabolism of Dapsone caused by Prednisolone mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [79]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Dapsone caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [116]
Sirolimus DMGW1ID Moderate Increased plasma concentrations of Dapsone and Sirolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [114]
Tacrolimus DMZ7XNQ Moderate Increased plasma concentrations of Dapsone and Tacrolimus due to competitive inhibition of the same metabolic pathway. Transplant rejection [NE84] [114]
Elagolix DMB2C0E Minor Increased metabolism of Dapsone caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [79]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Dapsone and Ganciclovir. Virus infection [1A24-1D9Z] [81]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Dapsone and Valganciclovir. Virus infection [1A24-1D9Z] [81]
⏷ Show the Full List of 82 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Carmellose sodium E00625 Not Available Disintegrant
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Dapsone 100 mg tablet 100 mg Oral Tablet Oral
Dapsone 25 mg tablet 25 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
2 BDDCS applied to over 900 drugs
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
8 Metabolic interactions of putative cytochrome P4503A substrates with alternative pathways of dapsone metabolism in human liver microsomes. Drug Metab Dispos. 1996 Feb;24(2):164-171.
9 CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab Dispos. 2000 Aug;28(8):865-8.
10 Differential activation of CYP2C9 variants by dapsone. Biochem Pharmacol. 2004 May 15;67(10):1831-41.
11 Drug Interactions Flockhart Table
12 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
13 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
14 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
15 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
17 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
19 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
21 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
22 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
23 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
24 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
25 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
26 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
27 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
28 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
29 Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
30 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
31 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
32 Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
33 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
34 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
35 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
36 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
37 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
38 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
39 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
40 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
41 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
42 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
43 Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
44 Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol. 2000 Dec;58(6):1341-8.
45 Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51. Arch Biochem Biophys. 1997 Feb 15;338(2):157-64.
46 Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol. 1996 Mar;9(2):365-73.
47 Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos. 2001 Mar;29(3):242-51.
48 Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles. Drug Metab Dispos. 1999 Jun;27(6):655-66.
49 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
50 Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol Rev. 2016 Jan;68(1):168-241.
51 Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics. 2003 Sep;13(9):565-75.
52 Analysis of human cytochrome P450 2C8 substrate specificity using a substrate pharmacophore and site-directed mutants. Biochemistry. 2004 Dec 14;43(49):15379-92.
53 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
54 PharmGKB summary: mycophenolic acid pathway. Pharmacogenet Genomics. 2014 Jan;24(1):73-9.
55 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
56 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
57 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
58 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
59 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
60 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
61 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
62 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
63 High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
64 Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
65 CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
66 Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
67 Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
68 Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20.
69 Cisplatin reduces Brucella melitensis-infected cell number by inducing apoptosis, oxidant and pro-inflammatory cytokine production. Res Vet Sci. 2010 Apr;88(2):218-26.
70 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
71 Thiols as peroxidase substrates. Free Radic Biol Med. 1993 Feb;14(2):167-75.
72 Proteomic profile of aminoglutethimide-induced apoptosis in HL-60 cells: role of myeloperoxidase and arylamine free radicals. Chem Biol Interact. 2015 Sep 5;239:129-38.
73 Divergent cyclooxygenase responses to fatty acid structure and peroxide level in fish and mammalian prostaglandin H synthases. FASEB J. 2006 Jun;20(8):1097-108.
74 Structural basis of fatty acid substrate binding to cyclooxygenase-2. J Biol Chem. 2010 Jul 16;285(29):22152-63.
75 Health implications of high dietary omega-6 polyunsaturated Fatty acids. J Nutr Metab. 2012;2012:539426.
76 PharmGKB summary: very important pharmacogene information for PTGS2. Pharmacogenet Genomics. 2011 Sep;21(9):607-13.
77 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
78 Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
79 Product Information. Aczone (dapsone topical). QLT USA, Inc, Fort Collins, CO.
80 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
81 Cerner Multum, Inc. "Australian Product Information.".
82 Product Information. Synercid (dalfopristin-quinupristin) Rhone-Poulenc Rorer, Collegeville, PA.
83 Product Information. Tykerb (lapatinib). Novartis Pharmaceuticals, East Hanover, NJ.
84 Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
85 Product Information. Raxar (grepafloxacin). Glaxo Wellcome, Research Triangle Park, NC.
86 Product Information. Korlym (mifepristone). Corcept Therapeutics Incorporated, Menlo Park, CA.
87 Product Information. Kalydeco (ivacaftor). Vertex Pharmaceuticals, Cambridge, MA.
88 Product Information. Prevymis (letermovir). Merck & Company Inc, Whitehouse Station, NJ.
89 Product Information. Emend (aprepitant). Merck & Company Inc, West Point, PA.
90 Product Information. Serzone (nefazodone). Bristol-Myers Squibb, Princeton, NJ.
91 Auclair B, Berning SE, Huitt GA, Peloquin CP "Potential interaction between itraconazole and clarithromycin." Pharmacotherapy 19 (1999): 1439-44. [PMID: 10600094]
92 Borcherding SM, Baciewicz AM, Self TH "Update on rifampin drug interactions." Arch Intern Med 152 (1992): 711-6. [PMID: 1558427]
93 Product Information. Priftin (rifapentine). Hoechst Marion-Roussel Inc, Kansas City, MO.
94 Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
95 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
96 Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
97 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
98 Olkkola KT, Palkama VJ, Neuvonen PJ "Ritonavir's role in reducing fentanyl clearance and prolonging its half-life." Anesthesiology 91 (1999): 681-5. [PMID: 10485779]
99 Abernethy DR, Egan JM, Dickinson TH, Carrum G "Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans." J Pharmacol Exp Ther 244 (1988): 994-9. [PMID: 3252045]
100 Goodwin C, Sparell G "Inhibition of dapsone excretion by probenecid." Lancet 2 (1969): 884. [PMID: 4186460]
101 Blakely KM, Drucker AM, Rosen CF "Drug-induced photosensitivity-an update: Culprit drugs, prevention and management." Drug Saf 42 (2019): 827-47. [PMID: 30888626]
102 Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
103 Canadian Pharmacists Association.
104 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
105 Product Information. Tasigna (nilotinib). Novartis Pharmaceuticals, East Hanover, NJ.
106 Product Information. Gleevec (imatinib mesylate). Novartis Pharmaceuticals, East Hanover, NJ.
107 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
108 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
109 EMA. European Medicines Agency. European Union "EMA - List of medicines under additional monitoring.".
110 Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
111 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
112 Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
113 Product Information. Tracleer (bosentan). Acetelion Pharmaceuticals US, Inc, South San Francisco, CA.
114 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
115 DSouza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, Koch KM "Effect of alosetron on the pharmacokinetics of alprazolam." J Clin Pharmacol 41 (2001): 452-4. [PMID: 11304902]
116 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.